From Diagnosis to Treatment: Patient-Centered Care with the New CIDP Guidelines
Released On
January 31, 2023
Expires On
January 31, 2024
Media Type
Internet
Completion Time
60 minutes
Specialty
Allergy & Immunology, Emergency Medicine, Hospitalist, Neurology, Primary Care
Topic(s)
CIDP, Neuromuscular
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the GBS/CIDP Foundation.
This activity is supported by an educational grant from Grifols and CSL Behring.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
The target audiences for the proposed HCP activity are community neurologists, neuromuscular specialists, immunologists, PCPs, hospitalists, emergency physicians, APNs, RNs, pharmacists.
Program Overview
Differentiating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from other immune-mediated inflammatory neuropathies can be challenging for clinicians. Misdiagnoses are common and can lead to poor outcomes for patients. However, newly revised guidelines for CIDP offer an opportunity to address barriers to accurate diagnoses and appropriate treatments.
Join an expert panel of neurologists and representatives from the GBS|CIDP Foundation International to discuss disease aspects/variants, simplify accurate diagnoses, and offer evidence-based guidance on treatment options and selections. Panelists will cover the place of imaging technologies in diagnosis, recognition of CIDP based on symptoms, and testing recommendations in the 2021 guidelines. Clinicians will leave the activity better able to work with their patients to individualize treatments and incorporate emerging agents and immunoglobulin formulations as they are approved.
Educational Objectives
Upon completion of this activity, participants should be better able to:
- Integrate the 2021 European Academy of Neurology/Peripheral Nerve Society guidelines into the diagnosis and treatment of CIDP
- Summarize how new diagnostic criteria and use of imaging technology will improve the diagnosis of CIDP and its variants
- Formulate individualized treatment plans with the patient based on updated recommendations, patients’ quality of life, and measures of disability and impairment
- Summarize rationale for the need and data to date with new approaches to the treatment of CIDP, including new immunoglobulin formulations and FcRn receptor-targeted agents
Faculty
Dr. Jeffrey Allen
Associate Professor
University of Minnesota
Dr. Lisa Butler
Executive Director
GBS/CIDP Foundation International
Dr. Thomas Harbo
Associate Professor, Depart of Neurology
Aarhus University Hospital
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Relevant Financial Relationships
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
- Dr. Jeffrey Allen
-
- Co-Owner/Founder: Argenx, Alexion, Anylym, CSL behring, Grifols, Pfizer, Jannsen, Takeda, Immunovant, Immupharma
- Consulting Fee: Argenx, Alexion, CSL behring, Takeda
- Honoraria: Argenx, Anylym, CSL behring
Dr. Lisa Butler, has nothing to disclose.
- Dr. Thomas Harbo
-
- Honoraria: Argenx SE, Annexon, CSL Behring, Johnson & Johnson, Roche, and Beigene
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
Carole Drexel, has nothing to disclose.
Caroline Laurendeau, has nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Method of Participation
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
There is no fee for this educational activity.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive at 877-394-1306 or at Support@NeuroSeriesLive.com.
PlatformQ Health Privacy Policy:
By clicking “Start Activity” you are agreeing to PlatformQ Health’s privacy policy. PlatformQ Health takes your privacy very seriously. The full Privacy Policy found here describes (i) the types of information we collect from you when you visit our Site; (ii) how we use the information we collect; (iii) with whom and why we share it; and (iv) the choices we offer regarding our use of the information. We also describe how to contact us about our privacy practices.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting support@PlatformQHealth.com with the subject line “Data Request”
You acknowledge and agree that by beginning this activity, you have affirmatively agreed to this Privacy Policy and consented to receiving electronic messages in conformance with this Privacy Policy. Please read the full privacy policy located at: www.platformqhealth.com/privacy-policy/